Bio-Techne in the news
Protein and diagnostics solutions
Tamtam found 20 recent articles about Bio-Techne.
- Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne stock demonstrated market strength by outperforming industry peers during a recent trading day.
- Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. stock outperformed its industry rivals during a strong day of market trading.
- New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
Bio-Techne and Refeyn launched a streamlined protein characterization workflow for bispecific antibodies to drive growth in high-margin instrumentation.
- 3 Reasons TECH is Risky and 1 Stock to Buy Instead
Bio-Techne is facing financial underperformance characterized by slow organic growth, a lack of scale in the life sciences sector, and diminishing returns on invested capital.
- Bio-Techne Corporation Trade Ideas — XETR:TE1
Trading strategies and market analysis perspectives for Bio-Techne Corporation's stock on the XETR exchange.
- Debt to equity ratio of Bio-Techne Corporation – XETR:TE1
Financial metrics and database attribution for Bio-Techne Corporation's debt to equity ratio.
- Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization
Bio-Techne and Refeyn have launched a combined workflow for characterization of bispecific antibodies and biosimilars using icIEF fractionation and mass photometry.
- Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Bio-Techne's stock rose 4.5% post-earnings despite missing revenue and profit estimates due to significant operating margin expansion and cost reductions.
- Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. stock outperformed its competitors during a strong day of market trading.
- New 4-hour test links charge and size in bispecific antibodies and biosimilars
A new four-hour workflow integrates icIEF fractionation with mass photometry to correlate antibody charge variants with molecular size.
- Bio-Techne and Refeyn launch workflow for antibody analysis By Investing.com
Bio-Techne and Refeyn have released a new integrated protein analysis workflow to speed up the characterization of complex bispecific antibodies.
- Bio-Techne Corporation and Refeyn Announces Integrated Workflow for Bispecific Antibody and Biosimilar Characterization
Bio-Techne and Refeyn have launched a four-hour integrated workflow that combines icIEF fractionation and mass photometry to characterize charge and size variants in complex biotherapeutics.
- Assessing Bio-Techne (TECH) Valuation After Recent Share Price Rebound And Mixed Longer Term Returns
Bio-Techne is refocusing on high-margin proteomic tools and automated platforms while navigating a complex valuation landscape marked by recent share price volatility.
- Bio-Techne and Refeyn launch integrated workflow for biologics analysis
Bio-Techne and Refeyn launched an integrated analytical workflow that combines protein charge separation and mass measurement to accelerate biologics development.
- Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
Bio-Techne and Refeyn launched a 4-hour workflow combining icIEF fractionation and mass photometry to accelerate the characterization of complex bispecific antibodies.
- Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains
Bio-Techne stock rose on Wednesday but lagged behind the performance of its industry peers.
- How Bio-techne Corp (TECH) Affects Rotational Strategy Timing
Financial analysis identifies a high risk-reward trading opportunity for Bio-Techne Corp based on positive momentum and mid-channel oscillation patterns.
- Bio-Techne Corp (TECH) Stock Analysis: Exploring A Potential 18.84% Upside
A financial analysis of Bio-Techne highlights a potential 18% stock upside based on its strong position in the protein sciences and diagnostics markets.
- Targeted Protein Degradation Broadens Its Scope
Advancements in targeted protein degradation are expanding to extracellular targets while Bio-Techne provides the specialized reagents and automated instruments needed for TPD research.
- Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Bio-Techne (TECH) and Agilent (A)
Analysts issued updated ratings and price targets for healthcare companies Quanterix, Bio-Techne, and Agilent.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Bio-Techne?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies